Baird Downgrades Sarepta Therapeutics To Neutral By: Benzinga via Benzinga October 28, 2014 at 07:54 AM EDT Analysts at Baird downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform to Neutral. The price target for Sarepta ... Read More >> Related Stocks: Sarepta Therapeutics